Profile data is unavailable for this security.
About the company
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
- Revenue in EUR (TTM)0.00
- Net income in EUR-14.76m
- Incorporated2006
- Employees19.00
- LocationGeneuro SA3, Chemin du Pre-FleuriPLAN-LES-OUATES 1228SwitzerlandCHE
- Phone+41 225524800
- Fax+41 227945086
- Websitehttps://www.geneuro.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biophytis SA | 0.00 | -15.07m | 1.24m | 22.00 | -- | -- | -- | -- | -6.54 | -6.54 | 0.00 | -1.22 | 0.00 | -- | -- | 0.00 | -129.28 | -97.52 | -- | -487.25 | -- | -- | -- | -- | -- | -5.75 | 5.28 | -- | -- | -- | 29.69 | -- | 14.25 | -- |
| Medesis Pharma SA | 0.00 | -3.96m | 2.09m | 10.00 | -- | -- | -- | -- | -0.7916 | -0.7916 | 0.00 | -0.9071 | 0.00 | 0.3139 | -- | -- | -206.12 | -126.10 | -- | -300.50 | -- | 70.78 | -- | -2,552.19 | 0.467 | -26.37 | -- | -- | -- | -- | -44.04 | -- | -- | -- |
| GeNeuro SA | 0.00 | -14.76m | 2.33m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| IntegraGen SA | 12.54m | -171.40k | 3.40m | 55.00 | -- | 1.66 | 126.72 | 0.271 | -0.025 | -0.025 | 1.90 | 0.3041 | 1.47 | 12.06 | 4.06 | 227,953.30 | -2.01 | -1.93 | -4.78 | -4.41 | 66.41 | 65.11 | -1.37 | -1.51 | 1.57 | -- | 0.3587 | -- | -4.78 | 12.61 | -4,783.19 | -- | -- | -- |
| Theranexus SA | 0.00 | -3.08m | 3.94m | 12.00 | -- | -- | -- | -- | -0.3971 | -0.3971 | 0.00 | -0.0004 | 0.00 | -- | -- | 0.00 | -50.35 | -42.66 | -64.95 | -47.97 | -- | -- | -- | -- | -- | -420.89 | 1.00 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 0.00 | -9.40m | 5.03m | 3.00 | -- | -- | -- | -- | -0.1519 | -0.1519 | 0.00 | -0.0255 | 0.00 | -- | -- | 0.00 | -282.86 | -60.77 | -422.81 | -102.24 | -- | -3,548.91 | -- | -3,374.13 | -- | -131.78 | 3.97 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -15.86m | 5.36m | 28.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.4011 | 0.00 | -- | -- | 0.00 | -129.36 | -- | -695.94 | -- | -- | -- | -- | -- | -- | -- | 3.71 | -- | -- | -- | -17.40 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Financi�re Arbevel SAas of 30 Dec 2022 | 530.58k | 1.78% |
| Clay Asset Management SASas of 30 Jun 2024 | 95.92k | 0.32% |
| Invesco Advisers, Inc.as of 31 Dec 2023 | 34.89k | 0.12% |
